Genialis and Inventia Life Science Collaborate to Link Patient Biology with 3D Pancreatic Cancer Models
The collaboration pairs the Genialis Supermodel with Inventia Life Science’s RASTRUM 3D cell model platform to test therapeutic hypotheses in models that mirror the tumor biology of specific patient groups. The post Genialis and Inventia Life Science Collaborate to Link Patient Biology with 3D Pancreatic Cancer Models appeared first on GEN - Genetic Engineering and Biotechnology News .
Genialis and Inventia Life Sciences have partnered to enhance the testing and matching of new pancreatic cancer treatments to the patients most likely to benefit. The collaboration marries Genialis' AI-powered patient insights with Inventia's RASTRUM 3D cell model platform to create human-relevant pancreatic ductal adenocarcinoma (PDAC) models that align with specific patient tumor biology.
Recent progress in targeted therapies for pancreatic cancer has led to a renewed focus on PDAC and the necessity for improved methods to determine which patients are most likely to benefit from novel treatments. Inventia's RASTRUM platform produces reproducible 3D pancreatic cancer models, enabling researchers to independently manipulate and modify tumor and stromal components.
Genialis characterizes these models using the Genialis Supermodel, a large molecular model trained on a proprietary harmonized and curated transcriptomics dataset, and links them to clinic-observed molecular states. This collaboration expands on Genialis' ongoing partnership with the Pancreatic Cancer Action Network (PanCAN).
In the upcoming study presented on September 25, Genialis identified PDAC patients with poor prognosis based on tumor microenvironment composition and activity across 644 patient tumors from the PanCAN SPARK "Know Your Tumor" cohort. By mapping these patient profiles to RASTRUM-generated tumor-fibroblast co-culture models, researchers can investigate the biology associated with poor outcomes and discover potential therapeutic strategies.
This partnership addresses an important gap in drug discovery by linking patient data with laboratory testability. Dr. Cameron Ferris, CEO and co-founder of Inventia Life Sciences, stated that Genialis can identify clinically meaningful biological states in real tumors, while RASTRUM allows for modeling and perturbing those states at scale. Together, they create a powerful method for generating and testing therapeutic hypotheses grounded in patient biology.
Ferris and Dr. Rafael Rosenbarten, CEO and co-founder of Genialis, emphasized that this collaboration bridges the gap between patient data analysis and preclinical testing, ultimately helping to determine which patients are most likely to benefit from specific treatments.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
